Key points are not available for this paper at this time.
as a therapeutic agent for liver diseases, presenting a novel approach for dual targeting with a simple conventional siRNA structure.
Share your take
Add a clinician perspective alongside expert commentary.
Ueda et al. (Tue,) studied this question.